

Learner Notification

MED Learning Group

Evaluating JAK Inhibition in Inflammatory Bowel Disease Management: Considering the Role of Novel Therapeutic Options

October 23, 2023 – October 23, 2024

Online

Acknowledgement of Financial Commercial Support

AbbVie, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Evaluate the importance of targeting JAK/STAT signaling in IBD from a pathophysiologic perspective and the role of JAK inhibition in modifying therapeutic outcomes.
2. Describe key unmet needs in IBD and the relevance of novel therapy in clinical management.
3. Interpret current perspectives in differential diagnosis, clinical assessment and the appropriate choice of effective therapy in IBD management.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Laura	Aibara	NA
Matthew	Frese	NA
Christina	Gallo	NA
Maia	Kayal	Bristol Myers Squibb, Fresenius, and Pfizer: Advisory Board, AbbVie: Consultant
Jessica	McMullen	NA
Aimee	Meissner	NA
Tara	Nelson-Mayfield	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com